coalit
epidem
prepared
innov
cepi
form
aftermath
ebola
outbreak
west
africa
support
develop
vaccin
could
improv
world
prepared
outbreak
epidem
infecti
diseas
sinc
launch
cepi
mobil
us
million
support
mission
develop
vaccin
agent
lassa
viru
middl
east
respiratori
syndrom
coronaviru
nipah
viru
well
sever
rapidrespons
vaccin
platform
acceler
respons
time
unexpect
epidem
threat
cepi
also
play
lead
role
foster
institut
partnership
publicand
privatesector
organ
optim
alloc
resourc
vaccin
develop
prioriti
pathogen
cepi
prioriti
includ
diversif
current
vaccin
research
develop
invest
portfolio
includ
addit
pathogen
rift
valley
fever
chikungunya
establish
technic
regulatori
pathway
vaccin
develop
across
cepi
portfolio
develop
sustain
manufactur
solut
vaccin
candid
near
complet
safeti
immunogen
test
human
creation
investig
stockpil
vaccin
candid
use
emerg
situat
commentari
provid
overview
global
health
challeng
cepi
establish
address
achiev
date
indic
prioriti
fund
coordin
come
year
recent
decad
world
shaken
emerg
spread
new
viral
diseas
although
world
respons
ebola
epidem
laudabl
gener
consensu
much
could
done
prevent
death
thousand
peopl
billion
dollar
econom
damag
result
epidem
despit
mani
laboratori
studi
candid
vaccin
trial
vesicular
stomat
virusebola
viru
vaccin
merck
kenilworth
new
jersey
guinea
vaccin
ever
develop
time
alter
cours
new
diseas
outbreak
vaccin
arriv
late
epidem
quit
recent
coordin
stakehold
respons
across
institut
sector
lag
behind
epidem
curv
emerg
infecti
diseas
eid
research
develop
r
prioriti
improv
prepared
driven
primarili
bioterror
concern
countri
leav
spars
product
develop
pipelin
eid
fall
outsid
nation
secur
agenda
addit
develop
eid
countermeasur
unapp
manufactur
see
littl
commerci
benefit
sporad
diseas
burden
lengthi
riski
costli
product
develop
challeng
notwithstand
west
african
ebola
epidem
led
paradigm
shift
eid
prepared
experiment
vaccin
therapeut
deploy
outbreak
thank
decad
r
biodefenserel
ebola
countermeasur
vesicular
stomat
virusebola
viru
vaccin
manufactur
merck
demonstr
effect
field
trial
howev
none
product
readi
deploy
time
chang
cours
outbreak
due
insuffici
clinic
data
safeti
efficaci
plu
absenc
product
stockpil
although
trial
assess
vesicular
stomat
virusebola
viru
vaccin
commenc
late
epidem
success
suggest
pathway
better
prepared
futur
epidem
name
advanc
biomed
countermeasur
human
trial
anticip
emerg
make
promis
quickli
avail
efficaci
test
use
emerg
occur
acknowledg
better
system
would
need
improv
world
prepared
respons
capac
futur
epidem
threat
sever
import
initi
launch
shortli
ebola
epidem
contain
may
world
bank
establish
pandem
emerg
financ
facil
quickli
releas
fund
affect
countri
epidem
respons
time
world
health
organ
publish
blueprint
prioriti
diseas
list
eid
prepared
respons
identifi
pathogen
potenti
caus
sever
outbreak
near
term
initi
list
may
compris
crimeancongo
hemorrhag
fever
prioriti
list
ebola
viru
diseas
marburg
viru
diseas
prioriti
list
lassa
fever
prioriti
list
merscov
sever
acut
respiratori
syndrom
prioriti
list
nipah
henipavir
diseas
prioriti
list
rift
valley
fever
prioriti
list
zika
viru
prioriti
list
diseas
x
prioriti
list
arenavir
hemorrhag
fever
lassa
fever
watchlist
chikungunya
watchlist
highli
pathogen
coronavir
diseas
mer
sever
acut
respiratori
syndrom
watchlist
emerg
nonpolio
enterovirus
includ
watchlist
sever
fever
thrombocytopenia
syndrom
watchlist
earlier
year
inspir
call
new
vaccin
fund
global
thought
leader
govern
industri
civil
societi
also
met
world
econom
forum
davo
switzerland
agre
explor
new
way
drive
product
innov
highprior
epidem
threat
davo
meet
task
team
conven
februari
june
defin
sustain
solut
develop
eid
vaccin
improv
global
prepared
respons
capac
task
team
compris
thought
leader
expert
repres
organ
drew
insight
blueprint
prioriti
industri
civilsocieti
perspect
role
vaccin
prevent
humanitarian
crise
caus
eid
task
team
explor
challeng
develop
eid
vaccin
could
use
epidem
includ
pathogen
priorit
clinic
develop
manufactur
capac
regulatori
pathway
model
product
develop
partnership
fund
strategi
task
team
recommend
led
format
coalit
epidem
prepared
innov
cepi
coalit
design
cepi
reflect
explicit
awar
organ
drive
vaccin
develop
known
eid
unknown
pathogen
epidem
potenti
ie
diseas
x
alon
togeth
multilater
collabor
approach
complex
vaccin
develop
deliveri
address
public
good
cepi
formal
launch
world
econom
forum
meet
davo
close
us
million
initi
fund
govern
norway
japan
germani
bill
melinda
gate
foundat
wellcom
cepi
initi
strateg
object
establish
aim
advanc
vaccin
candid
first
prioriti
pathogen
lassa
viru
merscov
nipah
viru
evid
safeti
immunogen
human
phase
establish
divers
portfolio
platform
technolog
acceler
develop
manufactur
clinic
evalu
vaccin
respons
outbreak
new
eid
design
diseas
x
januari
cepi
expand
list
prioriti
pathogen
includ
chikungunya
rift
valley
fever
accord
initi
estim
minimum
billion
would
requir
bring
least
eid
vaccin
end
phase
trial
fund
investig
stockpil
case
intern
health
emerg
two
year
oper
cepi
alreadi
secur
million
support
mission
contribut
govern
donor
european
commiss
philanthrop
organ
three
call
propos
issu
invit
applic
r
invest
two
call
invit
applic
vaccin
develop
specif
prioriti
eid
initi
lassa
viru
merscov
nipah
viru
recent
rift
valley
fever
chikungunya
anoth
call
invit
applic
rapidrespons
platform
technolog
acceler
develop
vaccin
respons
epidem
outbreak
known
eid
unexpectedli
emerg
infect
diseas
x
socal
vaccin
platform
technolog
compris
standard
reproduc
manufactur
process
adapt
produc
vaccin
differ
pathogen
flexibl
platform
improv
manufactur
effici
shorten
overal
time
frame
vaccin
develop
cepi
also
recent
invit
propos
bloodspecimen
collect
survivor
lassa
fever
support
improv
character
immun
respons
support
develop
assay
standard
approach
prove
effect
lassa
viru
cepi
also
consid
expand
merscov
nipah
viru
septemb
cepi
sign
partnership
agreement
vaccin
develop
partner
tabl
agreement
enabl
acceler
develop
lassa
merscov
nipah
rift
valley
fever
vaccin
candid
year
late
preclin
phase
phase
manufactur
investig
stockpil
use
largescal
efficaci
trial
outbreak
well
latestag
clinic
develop
advanc
chikungunya
vaccin
acceler
regulatori
approv
atrisk
popul
access
vaccin
far
cepi
initi
project
develop
vaccin
candid
prioriti
pathogensinclud
lassa
viru
merscov
nipah
viru
rift
valley
fever
chikungunyaand
vaccin
manufactur
platform
demonstr
advantag
platform
addit
vaccin
candid
produc
test
includ
influenza
rabi
merscov
marburg
viru
lassa
fever
respiratori
syncyti
viru
yellow
fever
approach
rna
vaccin
earlier
phase
develop
show
great
promis
applic
multipl
pathogen
rapid
product
addit
cepi
set
asid
fund
support
develop
ebola
vaccin
research
fund
complementari
current
effort
field
invest
coordin
funder
necessari
avoid
duplic
work
past
year
cepi
made
effort
engag
coordin
work
partner
throughout
global
health
vaccin
develop
ensur
sustain
approach
vaccin
develop
coalit
work
industri
partnersfrom
small
biotechnolog
compani
larg
manufacturersthrough
partnership
share
risk
vaccin
develop
tabl
cepi
also
coordin
effort
sever
multilater
partner
princip
interinstitut
roundtabl
refer
joint
coordin
group
joint
coordin
group
includ
key
organ
respons
vaccin
procur
deliveri
implement
well
repres
import
regulatori
agenc
work
identifi
way
predict
access
vaccin
prioriti
popul
achiev
emerg
situat
overal
goal
joint
coordin
group
optim
alloc
resourc
across
diseas
area
vaccin
develop
minim
fund
overlap
partner
improv
respons
time
unexpect
epidem
threat
prepar
next
epidem
requir
invest
platform
capabl
rapid
vaccin
develop
coordin
among
multipl
stakehold
cepi
coalit
partner
commit
substanti
resourc
attent
cepi
begin
turn
promis
progress
sever
challeng
ought
acknowledg
first
vaccin
develop
wide
acknowledg
long
complex
process
often
last
year
discoveri
licensur
second
vaccin
develop
inher
riski
least
twothird
preclin
vaccin
candid
like
fail
reach
clinic
proof
concept
view
risk
failur
full
cost
success
advanc
vaccin
candid
preclin
clinic
efficaci
trial
readi
emerg
use
vari
averag
million
million
cepi
far
commit
million
eid
vaccinedevelop
project
wherea
full
cost
vaccin
develop
expect
share
fund
develop
partner
concret
clinic
outcom
like
go
take
sever
year
materi
vaccin
develop
eid
priorit
averag
billion
would
need
support
vaccin
develop
phase
trial
depend
cost
structur
vaccin
develop
program
r
pipelin
attrit
improv
coordin
among
industri
global
health
civilsocieti
institut
guidanc
regul
also
need
determin
public
health
need
key
diseas
iron
technic
regulatori
pathway
feasibl
vaccin
develop
addit
resourc
becom
avail
cepi
diversifi
current
vaccin
r
invest
portfolio
includ
addit
pathogen
begin
chikungunya
debilit
mosquitoborn
diseas
spread
aed
aegypti
albopictu
affect
million
peopl
global
rift
valley
fever
viral
zoonosi
cattl
domest
livestock
also
infect
human
chikungunya
infect
lead
substanti
morbid
patient
experi
arthralgia
month
even
year
chronic
inflammatori
rheumat
diseas
develop
small
subset
patient
substanti
burden
diseas
exampl
coupl
larg
vaccin
pipelin
rel
eid
could
justifi
invest
might
yield
clinic
relev
outcom
shorter
time
quantiti
antigen
gener
expect
differ
across
eid
howev
know
quantiti
antibodi
would
requir
induc
protect
chikungunya
could
make
identif
situat
would
allow
statist
demonstr
efficaci
challeng
feasibl
develop
would
consequ
depend
technic
hurdl
regulatori
guidanc
appropri
clinic
trial
design
case
rift
valley
fever
outbreak
occur
confirm
suspect
case
death
viral
transmiss
peopl
occur
primarili
contact
blood
organ
infect
anim
howev
aed
culex
mosquito
also
act
viral
reservoir
vector
rift
valley
fever
wide
geograph
rang
spread
throughout
africa
saudi
arabian
peninsula
risk
spread
europ
north
america
also
high
licens
vaccin
avail
human
use
least
vaccin
candid
current
phase
trial
definit
regulatori
pathway
clinic
trial
emerg
use
need
account
specif
vaccin
challeng
pose
eid
present
unclear
regulatori
process
vaccin
candid
could
acceler
event
outbreak
known
eid
diseas
x
enhanc
regulatori
guidanc
norm
direct
coalit
partner
need
approv
clinic
trial
equit
access
eid
vaccin
outbreak
priorit
variou
countermeasur
eg
human
vaccin
vs
anim
vaccin
combin
might
also
requir
optim
develop
effect
prepared
strategi
unexpect
emerg
relat
eid
outbreak
rift
valley
fever
merscov
eid
threat
evolv
increas
coordin
public
health
agenc
worldwid
requir
ensur
product
develop
priorit
accordingli
sustain
manufactur
solut
also
need
negoti
soon
vaccin
candid
near
complet
safeti
immunogen
test
human
mechan
fund
maintain
global
stockpil
investig
vaccin
must
establish
vaccin
candid
continu
move
develop
cepi
coalit
partner
soon
must
lay
concret
plan
procur
stockpil
system
could
establish
much
system
would
cost
would
oper
would
need
operation
eid
remain
major
threat
global
health
secur
year
ebola
outbreak
west
africa
threat
like
grow
come
year
variou
ecolog
demograph
econom
factor
acceler
diseas
emerg
reemerg
alon
outbreak
prioriti
pathogen
includ
separ
ebola
outbreak
democrat
republ
congo
thank
thousand
dose
vesicular
stomat
virusebola
viru
vaccin
alreadi
manufactur
vaccin
rollout
help
avert
largescal
epidem
context
ebola
cepi
plan
make
r
invest
complement
current
research
effort
thank
partnership
effort
cepi
broad
rang
vaccin
develop
vaccin
candid
lassa
fever
merscov
nipah
viru
develop
rift
valley
vaccin
candid
initi
latestag
preclin
develop
chikungunya
vaccin
candid
resum
latestag
clinic
develop
addit
cepi
fund
vaccin
candid
hope
meet
safeti
immunogen
profil
requir
investig
stockpil
use
larg
clinic
trial
humanitarian
respons
outbreak
condit
develop
rapidrespons
platform
technolog
threaten
eid
also
initi
includ
pilot
lassa
fever
merscov
influenza
rabi
respiratori
syncyti
viru
marburg
viru
yellow
fever
cepi
continu
enhanc
epidem
prepared
target
fund
technic
oversight
ultim
howev
cepi
success
depend
strength
coalit
collabor
effort
across
sector
institut
geograph
region
develop
effect
eid
vaccin
ensur
equit
access
global
health
emerg
